Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BL-B01D1 plus toripalimab in unresectable locally advanced or recurrent/metastatic triple-negative breast cancer
CTR20242251Phase 2Active
- Sponsor
- Biokin Pharmaceutical
- Start
- Aug 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of izalontamab brengitecan, toripalimab in triple-negative breast cancer (TNBC), sponsored by Biokin Pharmaceutical. Started Aug 2024; status: active.
02
Drugs
izalontamab brengitecantoripalimab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on CTR20242251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242251.